De novo design: From models to molecules

De novo Molecular Design

Volumn , Issue , 2013, Pages 1-55

  Schneider, Gisbert ^a   Baringhaus, Karl Heinz ^b  

^a ETH ZURICH   (Switzerland)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

de novo molecular design; Drug design; Drug discovery; Machine learning; Medicinal chemistry; Molecular design cycle; Molecular modeling; Structure activity relationships

Indexed keywords

CHEMICAL ANALYSIS; LEARNING SYSTEMS; MOLECULAR MODELING;

DRUG DESIGN; DRUG DISCOVERY; MEDICINAL CHEMISTRY; MOLECULAR DESIGN; STRUCTURE ACTIVITY RELATIONSHIPS;

STRUCTURAL DESIGN;

EID: 85016308650     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527677016.ch1     Document Type: Chapter

References (245)

1. Sullivan, H.L. (1896) The Tall Office Building Artistically Considered. Lippincott's Monthly Magazine, issue 57, pp. 403-409.
2. Dalton, J. (1842) A New System of Chemical Philosophy, John Weale, London, pp. 237-239.
3. Kaufmann, S. (1993) Origins of Order: Self-Organization and Selection in Evolution, Oxford University Press, Oxford.
4. Holland, J.H. (1998) Emergence -From Chaos to Order, Oxford University Press, Oxford.
5. Freeman, W.J., Kozma, R., and Werbos, P.J. (2001) Biocomplexity: adaptive behavior in complex stochastic dynamical systems. Biosystems, 59, 109-123.
6. Mashaal, M. (2006) Bourbaki: A Secret Society of Mathematicians, American Mathematical Society, Providence, RI.
7. Tillich, P. (1951) Systematic Theology I, University of Chicago Press, Chicago.
8. Todeschini, R. and Consonni, V. (2000) Handbook of Molecular Descriptors, Wiley-VCH Verlag GmbH, Weinheim.
9. King, R.D., Muggleton, S., Lewis, R.A., and Sternberg, M.J. (1992) Drug design by machine learning: the use of inductive logic programming to model the structure-activity relationships of trimethoprim analogues binding to dihydrofolate reductase. Proc. Natl. Acad. Sci. U.S.A., 89, 11322-11326.
10. Lee, B. and Richards, F.M. (1971) The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol., 55, 379-400.
11. Connolly, M.L. (1983) Solventaccessible surfaces of proteins and nucleic acids. Science, 221, 709-713.
12. Ballester, P.J. (2011) Ultrafast shape recognition: method and applications. Future Med. Chem., 3, 65-78.
13. Ebalunode, J.O. and Zheng, W. (2010) Molecular shape technologies in drug discovery: methods and applications. Curr. Top. Med. Chem., 10, 669-679.
14. Cramer, R. III, Patterson, D., and Bunce, J. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 110, 5959-5967.
15. Randic, M., Kleiner, A., and Alba, L.D. (1994) Distance/distance matrices. J. Chem. Inf. Comput. Sci., 34, 277-286.
16. Schuur, J. and Gasteiger, J. (1997) Infrared spectra simulation of substituted benzene derivatives on the basis of a 3D structure representation. Anal. Chem., 69, 2398-2405.
17. Robinson, D., Barlow, T., and Richards, G. (1997) The utilization of reduced dimensional representations of molecular structure for rapid molecular similarity calculations. J. Chem. Inf. Comput. Sci., 37, 943-950.
18. Hemmer, M., Steinhauer, V., and Gasteiger, J. (1999) Deriving the 3D structure of organic molecules from their infrared spectra. Vib. Spectrosc., 19, 151-164.
19. Gramatica, P., Corradi, M., and Consonni, V. (2000) Modelling and prediction of soil sorption coefficients of non-ionic organic pesticides by molecular descriptors. Chemosphere, 41, 763-777.
20. Ballester, P.J. and Richards, W.G. (2007) Ultrafast shape recognition to search compound databases for similar molecular shapes. J. Comput. Chem., 28, 1711-1723.
21. Grant, A., Gallardo, A., and Pickup, B. (1996) A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J. Comput. Chem., 17, 1653-1666.
22. Cruciani, G., Crivori, P., Carrupt, P.A., and Testa, B. (2000) Molecular fields in quantitative structurepermeation relationships: the VolSurf approach. J. Mol. Struct., 503, 17-30.
23. Consonni, V., Todeschini, R., Pavan, M., and Gramatica, P. (2002) Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 2. Application of the novel 3D molecular descriptors to QSAR/QSPR studies. J. Chem. Inf. Comput. Sci., 42, 693-705.
24. Van Drie, J.H. (1997) ''Shrink-wrap'' surfaces: a new method for incorporating shape into pharmacophoric 3D database searching. J. Chem. Inf. Comput. Sci., 37, 38-42.
25. Ritchie, D. and Kemp, G. (1999) Fast computation, rotation, and comparison of low resolution spherical harmonic molecular surfaces. J. Comput. Chem., 20, 383-395.
26. Morris, R.J., Najmanovich, R.J., Kahraman, A., and Thornton, J.M. (2005) Real spherical harmonic expansion coefficients as 3D shape descriptors for protein binding pocket and ligand comparisons. Bioinformatics, 21, 2347-2355.
27. Ṕerez-Nueno, V.I., Venkatraman, V., Mavridis, L., Clark, T., and Ritchie, D.W. (2011) Using spherical harmonic surface property representations for ligand-based virtual screening. Mol. Inf., 30, 151-159.
28. Jakobi, A.J., Mauser, H., and Clark, T. (2008) Parafrag-an approach for surface-based similarity comparison of molecular fragments. J. Mol. Model., 14, 547-558.
29. Rechenberg, I. (1973) Evolutionsstrategie-Optimierung Technischer Systeme Nach Prinzipien der biologischen Evolution, Frommann-Holzboog, Stuttgart.
30. Johnson, M.A. and Maggiora, G.M. (eds) (1990) Concepts and Applications of Molecular Similarity, John Wiley & Sons, Inc., New York.
31. Guha, R. (2011) The ups and downs of structure-activity landscapes. Methods Mol. Biol., 672, 101-117.
32. Bajorath, J., Peltason, L., Wawer, M., Guha, R., Lajiness, M.S., and Van Drie, J.H. (2009) Navigating structure-activity landscapes. Drug Discov. Today, 14, 698-705.
33. Bongard, M.M. (1970) Pattern Recognition, Hayden Book Co., Spartan Books, Rochelle Park, NJ(Original publication: , Nauka Press, Moscow, 1967).
34. Miller, J.H. and Page, S.E. (2007) Complex Adaptive Systems -An Introduction to Computational Models of Social Life, Princeton University Press, Pronceton, NJ, Oxford.
35. Koza, J.R. (1992) Genetic Programming: On the Programming of Computers by Means of Natural Selection, The MIT Press, Cambridge.
36. Böhm, H.J. and Schneider, G. (eds) (2003) Protein-Ligand Interactions: From Molecular Recognition to Drug Design. Methods and Principles in Medicinal Chemistry, Vol. 19 (eds R. Mannhold, H. Kubinyi, and G. Folkers), Wiley-VCH Verlag GmbH, Weinheim.
37. Desiraju, G.R. (2002) Hydrogen bridges in crystal engineering: interactions without borders. Acc. Chem. Res., 35, 565-573.
38. Butler, K.T., Luque, F.J., and Barril, X. (2009) Toward accurate relative energy predictions of the bioactive conformation of drugs. J. Comput. Chem., 30, 601-610.
39. Poehlsgaard, J., Harpsøe, K., Jørgensen, F.S., and Olsen, L. (2012) A robust force field based method for calculating conformational energies of charged drug-like molecules. J. Chem. Inf. Model., 52, 409-419.
40. Agrafiotis, D.K., Gibbs, A.C., Zhu, F., Izrailev, S., and Martin, E. (2007) Conformational sampling of bioactive molecules: a comparative study. J. Chem. Inf. Model., 47, 1067-1086.
41. Foloppe, N. and Chen, I.J. (2009) Conformational sampling and energetics of drug-like molecules. Curr. Med. Chem., 16, 3381-3413.
42. Biela, A., Betz, M., Heine, A., and Klebe, G. (2012) Water makes the difference: rearrangement of water solvation layer triggers non-additivity of functional group contributions in protein-ligand binding. ChemMedChem, 7, 1423-1434.
43. Dimova, D., Heikamp, K., Stumpfe, D., and Bajorath, J. (2013) Do medicinal chemists learn from activity cliffs? A systematic evaluation of cliff progression in evolving compound data sets. J. Med. Chem., 56, 3339-3345.
44. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., and Bourne, P.E. (2000) The protein data bank. Nucleic Acids Res., 28, 235-242.
45. Fischer, S. and Verma, C.S. (1999) Binding of buried structural water increases the flexibility of proteins. Proc. Natl. Acad. Sci. U.S.A, 96, 9613-9615.
46. Bissantz, C., Kuhn, B., and Stahl, M. (2010) A medicinal chemist's guide to molecular interactions. J. Med. Chem., 53, 5061-5084.
47. Hann, M.M. and Keserü, G.M. (2012) Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov., 11, 355-365.
48. Ferenczy, G.G. and Keserü, G.M. (2010) Enthalpic efficiency of ligand binding. J. Chem. Inf. Model., 50, 1536-1541.
49. Freire, E. (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today, 13, 869-874.
50. Hopkins, A.L., Groom, C.R., and Alex, A. (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 9, 430-431.
51. Keserü, G.M. and Makara, G.M. (2009) The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov., 8, 203-212.
52. Walters, W.P. and Namchuk, M. (2003) Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov., 2, 259-266.
53. Reutlinger, M. and Schneider, G. (2012) Nonlinear dimensionality reduction and mapping of compound libraries for drug discovery. J. Mol. Graph. Model., 34, 108-117.
54. Pearson, K. (1901) Philos. Mag., 2, 559-572.
55. St°ahle, L. and Wold, S. (1986) On the use of some multivariate statistical methods in pharmacological research. J. Pharmacol. Methods, 16, 91-110.
56. Kohonen, T. (1982) Self-organized formation of topologically correct feature maps. Biol. Cybern., 43, 59-69.
57. Torgerson, W.S. (1952) Multidimensional scaling: I. Theory and method. Psychometrika, 17, 401-419.
58. Agrafiotis, D.K. and Xu, H. (2003) A geodesic framework for analyzing molecular similarities. J. Chem. Inf. Comput. Sci., 43, 475-484.
59. Reutlinger, M., Guba, W., Martin, R.E., Alanine, A.I., Hoffmann, T., Klenner, A., Hiss, J.A., Schneider, P., and Schneider, G. (2011) Neighborhood-preserving visualization of adaptive structure-activity landscapes: application to drug discovery. Angew. Chem. Int. Ed., 50, 11633-11636.
60. Reisine, T. and Bell, G.I. (1995) Molecular biology of somatostatin receptors. Endocrinol. Rev., 16, 427-442.
61. Martin, R.E., Green, L.G., Guba, W., Kratochwil, N., and Christm, A. (2007) Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J. Med. Chem., 50, 6291-6294.
62. Richardson, J.S., Richardson, D.C., Tweedy, N.B., Gernert, K.M., Quinn, T.P., Hecht, M.H., Erickson, B.W., Yan, Y., Mc Clain, R.D., and Donlan, M.E. (1992) Looking at proteins: representations, folding, packing, and design. Biophys. J., 63, 1185-1209.
63. Gertrudes, J.C., Maltarollo, V.G., Silva, R.A., Oliveira, P.R., Hońorio, K.M., and da Silva, A.B. (2012) Machine learning techniques and drug design. Curr. Med. Chem., 19, 4289-4297.
64. Chen, B., Harrison, R.F., Papadatos, G., Willett, P., Wood, D.J., Lewell, X.Q., Greenidge, P., and Stiefl, N. (2007) Evaluation of machinelearning methods for ligand-based virtual screening. J. Comput. Aided Mol. Des., 21, 53-62.
65. Melville, J.L., Burke, E.K., and Hirst, J.D. (2009) Machine learning in virtual screening. Comb. Chem. High Throughput Screening, 12, 332-343.
66. Schneider, G. and So, S.S. (2001) Adaptive Systems in Drug Design, Landes Bioscience, Austin, TX.
67. Baldi, P., Brunak, S., Chauvin, Y., Andersen, C.A.F., and Nielsen, H. (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics, 16, 412-424.
68. Matthews, B.W. (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim. Biophys. Acta, 405, 442-451.
69. Clark, R.D. and Webster-Clark, D.J. (2008) Managing bias in ROC curves. J. Comput. Aided Mol. Des., 22, 141-146.
70. Truchon, J.F. and Bayly, C.I. (2007) Evaluating virtual screening methods: good and bad metrics for the ''early recognition'' problem. J. Chem. Inf. Model., 47, 488-508.
71. Nicholls, A. (2011) What do we know? Simple statistical techniques that help. Methods Mol. Biol., 672, 531-581.
72. Funatsu, K., Miyao, T., and Arakawa, M. (2011) Systematic generation of chemical structures for rational drug design based on QSAR models. Curr. Comput. Aided Drug Des., 7, 1-9.
73. Roy, K. (2007) On some aspects of validation of predictive quantitative structure-activity relationship models. Expert Opin. Drug Discov., 2, 1567-1577.
74. Bender, A. (2011) Bayesian methods in virtual screening and chemical biology. Methods Mol. Biol., 672, 175-196.
75. Duda, R., Hart, P., and Stork, D. (2001) Pattern Classification, John Wiley & Sons, Inc., New York.
76. Besnard, J., Ruda, G.F., Setola, V., Abecassis, K., Rodriguiz, R.M., Huang, X.P., Norval, S., Sassano, M.F., Shin, A.I., Webster, L.A., Simeons, F.R., Stojanovski, L., Prat, A., Seidah, N.G., Constam, D.B., Bickerton, G.R., Read, K.D., Wetsel, W.C., Gilbert, I.H., Roth, B.L., and Hopkins, A.L. (2012) Automated design of ligands to polypharmacological profiles. Nature, 492, 215-220.
77. Zou, J., Han, Y., and So, S.S. (2008) Overview of artificial neural networks. Methods Mol. Biol., 458, 15-23.
78. Zupan, J. and Gasteiger, J. (1999) Neural Networks in Chemistry and Drug Design-an Introduction, Wiley-VCH Verlag GmbH, Weinheim.
79. Bishop, C. (1996) Neural Networks for Pattern Recognition, Oxford University Press, Oxford.
80. Tetko, I.V. (2008) Associative neural network. Methods Mol. Biol., 458, 185-202.
81. Schölkopf, B. and Smola, A. (2002) Learning with Kernels, MIT Press, Cambridge.
82. Schölkopf, B., Smola, A., and Müller, K.R. (1998) Nonlinear component analysis as a kernel eigenvalue problem. Neural Comput., 10, 1299-1319.
83. Burbidge, R., Trotter, M., Buxton, B., and Holden, S. (2001) Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comput. Chem., 26, 5-14.
84. Wassermann, A.M., Geppert, H., and Bajorath, J. (2011) Application of support vector machine-based ranking strategies to search for target-selective compounds. Methods Mol. Biol., 672, 517-530.
85. Schwaighofer, A., Schroeter, T., Mika, S., Laub, J., Laak, A., Sülzle, D., Ganzer, U., Heinrich, N., and Müller, K.R. (2007) Accurate solubility prediction with error bars for electrolytes: a machine learning approach. J. Chem. Inf. Model., 47, 407-424.
86. Obrezanova, O., Csanyi, G., Gola, J.M., and Segall, M.D. (2007) Gaussian processes: a method for automatic QSAR modeling of ADME properties. J. Chem. Inf. Model., 47, 1847-1857.
87. Hansen, K., Rathke, F., Schroeter, T., Rast, G., Fox, T., Kriegl, J.M., and Mika, S. (2009) Bias-correction of regression models: a case study on hERG inhibition. J. Chem. Inf. Model., 49, 1486-1496.
88. Schwaighofer, A., Schroeter, T., Mika, S., and Blanchard, G. (2009) How wrong can we get? A review of machine learning approaches and error bars. Comb. Chem. High Throughput Screening, 12, 453-468.
89. Rupp, M., Schroeter, T., Steri, R., Zettl, H., Proschak, E., Hansen, K., Rau, O., Schwarz, O., Müller-Kuhrt, L., Schubert-Zsilavecz, M., Müller, K.R., and Schneider, G. (2010) From machine learning to natural product derivatives that selectively activate transcription factor PPARgamma. ChemMedChem, 5, 191-194.
90. Rasmussen, C. and Williams, C. (2006) Gaussian Processes for Machine Learning, MIT Press, Cambridge.
91. Schneider, P. and Schneider, G. (2003) Collection of bioactive reference compounds for focused library design. QSAR Comb. Sci., 22, 713-718.
92. Reymond, J.L. and Awale, M. (2012) Exploring chemical space for drug discovery using the chemical universe database. ACS Chem. Neurosci., 3, 649-657.
93. Ruddigkeit, L., Blum, L.C., and Reymond, J.L. (2013) Visualization and virtual screening of the chemical universe database GDB-17. J. Chem. Inf. Model., 53, 56-65.
94. Schneider, G., Lee, M.L., Stahl, M., and Schneider, P. (2000) De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J. Comp. Aided Mol. Des., 14, 487-494.
95. Schneider, G., Cĺement-Chomienne, O., Hilfiger, L., Schneider, P., Kirsch, S., Böhm, H.J., and Neidhart, W. (2000) Virtual screening for bioactive molecules by evolutionary de novo design. Angew. Chem. Int. Ed., 39, 4130-4133.
96. Keserü, G.M. and Makara, G.M. (2006) Hit discovery and hit-to-lead approaches. Drug Discov. Today, 11, 741-748.
97. Hajduk, P.J. (2006) Fragment-based drug design: how big is too big? J. Med. Chem., 49, 6972-6976.
98. Ichihara, O., Barker, J., Law, R.J., and Whittaker, M. (2011) Compound design by fragment-linking. Mol. Inf., 30, 298-306.
99. Babaoglu, K. and Shoichet, B.K. (2006) Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol., 2, 720-723.
100. Murray, C.W. and Verdonk, M.L. (2002) The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput. Aided Mol. Des., 16, 741-753.
101. Hubbard, R.E., Chen, I., and Davis, B. (2007) Informatics and modeling challenges in fragment-based drug discovery. Curr. Opin. Drug Discov. Dev., 10, 289-297.
102. Nazaŕe, M., Matter, H., Will, D.W., Wagner, M., Urmann, M., Czech, J., Schreuder, H., Bauer, A., Ritter, K., and Wehner, V. (2012) Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. Angew. Chem. Int. Ed., 51, 905-911.
103. Hartenfeller, M., Zettl, H., Walter, M., Rupp, M., Reisen, F., Proschak, E., Weggen, S., Stark, H., and Schneider, G. (2012) DOGS: reactiondriven de novo design of bioactive compounds. PLoS Comput. Biol., 8, e1002380.
104. Schneider, G., Hartenfeller, M., Reutlinger, M., Tanrikulu, Y., Proschak, E., and Schneider, P. (2009) Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol., 27, 18-26.
105. Hiss, J.A., Hartenfeller, M., and Schneider, G. (2010) Concepts and applications of ''natural computing'' techniques in de novo drug and peptide design. Curr. Pharm. Des., 16, 1656-1665.
106. Hartenfeller, M., Proschak, E., Schüller, A., and Schneider, G. (2008) Concept of combinatorial de novo design of druglike molecules by particle swarm optimization. Chem. Biol. Drug Des., 72, 16-26.
107. Kutchukian, P.S., Lou, D., and Shakhnovich, E.I. (2009) FOG: Fragment optimized growth algorithm for the de novo generation of molecules occupying druglike chemical space. J. Chem. Inf. Model., 49, 1630-1642.
108. Lewell, X.Q., Judd, D., Watson, S., and Hann, M. (1998) RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci., 38, 511-522.
109. Makino, S., Ewing, T.J.A., and Kuntz, I.D. (1999) DREAM++: flexible docking program for virtual combinatorial libraries. J. Comput. Aided Mol. Des., 13, 513-532.
110. Vinkers, H.M., de Jonge, M.R., Daeyaert, F.F., Heeres, J., Koymans, L.M., van Lenthe, J.H., Lewi, P.J., Timmerman, H., Van Aken, K., and Janssen, P.A. (2003) Synopsis: synthesize and optimize system in silico. J. Med. Chem., 46, 2765-2773.
111. Gillett, V.J. (1995) SPROUT, HIPPO and CAESA: tools for de novo structure generation and estimation of synthetic accessibility. Perspect. Drug Discov. Des., 3, 34-50.
112. Zaliani, A., Boda, K., Seidel, T., Herwig, A., Schwab, C.H., Gasteiger, J., Claussen, H., Lemmen, C., Degen, J., Pärn, J., and Rarey, M. (2009) Second-generation de novo design: a view from a medicinal chemist perspective. J. Comput. Aided Mol. Des., 23, 593-602.
113. Law, J., Zsoldos, Z., Simon, A., Reid, D., Liu, Y., Khew, S.Y., Johnson, A.P., Major, S., Wade, R.A., and Ando, H.Y. (2009) Route designer: a retrosynthetic analysis tool utilizing automated retrosynthetic rule generation. J. Chem. Inf. Model., 49, 593-602.
114. Danziger, D.J. and Dean, P.M. (1989) Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogenbonding regions at protein surfaces. Proc. R. Soc. London, Ser. B, 236, 101-113.
115. Lewis, R.A. and Dean, P.M. (1989) Automated site-directed drug design: the concept of spacer skeletons for primary structure generation. Proc. R. Soc. London, Ser. B, 236, 125-140.
116. Gillett, V.A., Johnson, A.P., Mata, P., and Sike, S. (1990) Automated structure design in 3D. Tetrahedron Comp. Methodol., 3, 681-696.
117. Lewis, R.A., Roe, D.C., Huang, C., Ferrin, T.E., Langridge, R., and Kuntz, I.D. (1992) Automated site-directed drug design using molecular lattices. J. Mol. Graph., 10, 66-78.
118. Nishibata, Y. and Itai, A. (1991) Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron, 47, 8985-8990.
119. Nishibata, Y. and Itai, A. (1993) Confirmation of usefulness of a structure construction program based on threedimensional receptor structure for rational lead generation. J. Med. Chem., 36, 2921-2928.
120. Tschinke, V. and Cohen, N.C. (1993) The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypothesis. J. Med. Chem., 36, 3863-3870.
121. Ho, C.M.W. and Marshall, G.R. (1993) SPLICE: a program to assemble partial query solutions from three-dimensional database searches into novel ligands. J. Comput. Aided Mol. Des., 7, 623-647.
122. Rotstein, S.H. and Murcko, M.A. (1993) GroupBuild: a fragment-based method for de novo drug design. J. Med. Chem., 36, 1700-1710.
123. Pearlman, D.A. and Murcko, M.A. (1993) CONCEPTS: new dynamic algorithm for de novo design suggestion. J. Comput. Chem., 14, 1184-1193.
124. Gillet, V.J., Johnson, A.P., Mata, P., Sike, S., and Williams, P. (1993) SPROUT: a program for structure generation. J. Comput. Aided Mol. Des., 7, 127-153.
125. Gillet, V.J., Newell, W., Mata, P., Myatt, G., Sike, S., Zsoldos, Z., and Johnson, A.P. (1994) SPROUT: recent developments in the de novo design of molecules. J. Comput. Aided Mol. Des., 34, 207-217.
126. Mata, P., Gillet, V.J., Johnson, A.P., Lampreia, J., Myatt, G.J., Sike, S., and Stebbings, A.L. (1995) SPROUT: 3D structure generation using templates. J. Chem. Inf. Comput. Sci., 35, 479-493.
127. Eisen, M.B., Wiley, D.C., Karplus, M., and Hubbard, R.E. (1994) HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins, 19, 199-221.
128. Caflish, A., Miranker, A., and Karplus, M. (1993) Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J. Med. Chem., 36, 2142-2167.
129. Bohacek, R.S. and Mc Martin, C. (1994) Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J. Am. Chem. Soc., 116, 5560-5571.
130. Glen, R.C. and Payne, A.W. (1995) A genetic algorithm for the automated generation of molecules within constraints. J. Comput. Aided Mol. Des., 9, 181-202.
131. Clark, D.E., Frenkel, D., Levy, S.A., Li, J., Murray, C.W., Robson, B., Waszkowycz, B., and Westhead, D.R. (1995) PRO LIGAND: an approach to de novo molecular design. 1. Application to the design of organic molecules. J. Comput. Aided Mol. Des., 9, 13-32.
132. Waszkowycz, B., Clark, D.E., Frenkel, D., Li, J., Murray, C.W., Robson, B., and Westhead, D.R. (1994) PRO LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. J. Med. Chem., 37, 3994-4002.
133. Westhead, D.R., Clark, D.E., Frenkel, D., Li, J., Murray, C.W., Robson, B., and Waszkowycz, B. (1995) PRO LIGAND: an approach to de novo molecular design. 3. A genetic algorithm for structure refinement. J. Comput. Aided Mol. Des., 9, 139-148.
134. Frenkel, D., Clark, D.E., Li, J., Murray, C.W., Robson, B., Waszkowycz, B., and Westhead, D.R. (1995) PRO LIGAND: an approach de novo molecular design. 4. Application to the design of peptides. J. Comput. Aided Mol. Des., 9, 213-225.
135. Clark, D.E. and Murray, C.W. (1995) PRO LIGAND: an approach to de novo molecular design. 5. Tools for the analysis of generated structures. J. Chem. Inf. Comput. Sci., 35, 914-923.
136. Murray, C.W., Clark, D.E., and Byrne, D.G. (1995) PRO LIGAND: an approach to de novo molecular design. Flexible fitting in the design of peptides. J. Comput. Aided Mol. Des., 9, 381-395.
137. De Witte, R.S. and Shakhnovich, E.I. (1996) SMoG de novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. J. Am. Chem. Soc., 118, 11733-11744.
138. Ishchenko, A.V. and Shakhnovich, E.I. (2002) SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions. J. Med. Chem., 45, 2770-2780.
139. Grzybowski, B.A., Ishchenko, A.V., Kim, C.Y., Topalov, G., Chapman, R., Christianson, D.W., Whitesides, G.M., and Shakhnovich, E.I. (2002) Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc. Natl. Acad. Sci. U.S.A., 99, 1270-1273.
140. Pearlman, D.A. and Murcko, M.A. (1996) CONCERTS: dynamic connection of fragments as an approach to de novo ligand design. J. Med. Chem., 39, 1651-1663.
141. Luo, Z., Wang, R., and Lai, L. (1996) RASSE: a new method for structurebased drug design. J. Chem. Inf. Comput. Sci., 36, 1187-1194.
142. Murray, C.W., Clark, D.E., Auton, T.R., Firth, M.A., Li, J., Sykes, R.A., Waszkowycz, B., Westhead, D.R., and Young, S.C. (1997) PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. J. Comput. Aided Mol. Des., 11, 193-207.
143. Eldridge, M.D., Murray, C.W., Auton, T.R., Paolini, G.V., and Mee, R.P. (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des., 11, 425-445.
144. Todorov, N.P. and Dean, P.M. (1997) Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J. Comput. Aided Mol. Des., 11, 175-192.
145. Todorov, N.P. and Dean, P.M. (1998) A branch-and-bound method for optimal atom-type assignment in de novo ligand design. J. Comput. Aided Mol. Des., 12, 335-350.
146. Stahl, M., Todorov, N.P., James, T., Mauser, H., Böhm, H.J., and Dean, P.M. (2002) A validation study on the practical use of automated de novo design. J. Comput. Aided Mol. Des., 16, 459-478.
147. Nachbar, R.B. (1998) Molecular evolution: a hierarchical representation for chemical topology and its automated manipulation. Proceedings of the 3rd Annual Genetic Programming Conference, pp. 246-253;
148. Nachbar, R.B. (2000) Molecular evolution: automated manipulation of hierarchical chemical topology and its application to average molecular structures. Genet. Program. Evolv. Mach., 1, 57-94.
149. Globus, A., Lawton, J., and Wipke, W.T. (1999) Automatic molecular design using evolutionary algorithms. Nanotechnology, 10, 290-299.
150. Liu, H., Duan, Z., Luo, Q., and Shi, Y. (1999) Structure-based ligand design by dynamically assembling molecular building blocks at binding site. Proteins, 36, 462-470.
151. Zhu, J., Yu, H., Fan, H., Liu, H., and Shi, Y. (2001) Design of selective inhibitors of cyclooxygenase-2 dynamic assembly of molecular building blocks. J. Comput. Aided Mol. Des., 15, 447-463.
152. Douguet, D., Thoreau, E., and Grassy, G. (2000) A genetic algorithm for the automated generation of small organic molecules: drug design using an evolutionary algorithm. J. Comput. Aided Mol. Des., 14, 449-466.
153. Wang, R., Gao, Y., and Lai, L. (2000) LigBuilder: a multi-purpose program for structure-based drug design. J. Mol. Model., 6, 498-516.
154. Zhu, J., Fan, H., Liu, H., and Shi, Y. (2001) Structure-based ligand design for flexible proteins: application of new F-DycoBlock. J. Comput. Aided Mol. Des., 15, 979-996.
155. Pegg, S.C.H., Haresco, J.J., and Kuntz, I.D. (2001) A genetic algorithm for structure-based de novo design. J. Comput. Aided Mol. Des., 15, 911-933.
156. Pellegrini, E. and Field, M.J. (2003) Development and testing of a de novo drug-design algorithm. J. Comput. Aided Mol. Des., 17, 621-641.
157. Brown, N., Mc Kay, B., Gilardoni, F., and Gasteiger, J. (2004) A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules. J. Chem. Inf. Comput. Sci., 44, 1079-1087.
158. Pierce, A.C., Rao, G., and Bemis, G.W. (2004) BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease. J. Med. Chem., 47, 2768-2775.
159. Nikitin, S., Zaitseva, N., Demina, O., Solovieva, V., Mazin, E., Mikhalev, S., Smolov, M., Rubinov, A., Vlasov, P., Lepikhin, D., Khachko, D., Fokin, V., Queen, C., and Zosimov, V. (2005) A very large diversity space of synthetically accessible compounds for use with drug design programs. J. Comput. Aided Mol. Des., 19, 47-63.
160. Douguet, D., Munier-Lehmann, H., Labesse, G., and Pochet, S. (2005) LEA3D: a computer-aided ligand design for structure-based drug design. J. Med. Chem., 48, 2457-2468.
161. Fechner, U. and Schneider, G. (2006) Flux (1): a virtual synthesis scheme for fragment-based de novo design. J. Chem. Inf. Model., 46, 699-707.
162. Fechner, U. and Schneider, G. (2007) Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design. J. Chem. Inf. Model., 47, 656-667.
163. Degen, J. and Rarey, M. (2006) FlexNovo: structure-based searching in large fragment spaces. ChemMedChem, 1, 854-868.
164. Feher, M., Gao, Y., Baber, C., Shirley, W.A., and Saunders, J. (2008) The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies. Bioorg. Med. Chem., 16, 422-427.
165. Dey, F. and Caflisch, A. (2008) Fragment-based de novo ligand design by multiobjective evolutionary optimization. J. Chem. Inf. Model., 48, 679-690.
166. Proschak, E., Sander, K., Zettl, H., Tanrikulu, Y., Rau, O., Schneider, P., Schubert-Zsilavecz, M., Stark, H., and Schneider, G. (2009) From molecular shape to potent bioactive agents II: fragment-based de novo design. ChemMedChem, 4, 45-48.
167. Proschak, E., Zettl, H., Tanrikulu, Y., Weisel, M., Kriegl, J.M., Rau, O., Schubert-Zsilavecz, M., and Schneider, G. (2009) From molecular shape to potent bioactive agents I: bioisosteric replacement of molecular fragments. ChemMedChem, 4, 41-44.
168. Hecht, D. and Fogel, G.B. (2009) A novel in silico approach to drug discovery via computational intelligence. J. Chem. Inf. Model., 49, 1105-1121.
169. Moriaud, F., Doppelt-Azeroual, O., Martin, L., Oguievetskaia, K., Koch, K., Vorotyntsev, A., Adcock, S.A., and Delfaud, F. (2009) Computational fragment-based approach at PDB scale by protein local similarity. J. Chem. Inf. Model., 49, 280-294.
170. Nicolaou, C.A., Apostolakis, J., and Pattichis, C.S. (2009) De novo drug design using multiobjective evolutionary graphs. J. Chem. Inf. Model., 49, 295-307.
171. Nisius, B. and Rester, U. (2009) Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design. J. Chem. Inf. Model., 49, 1211-1222.
172. Durrant, J.D., Amaro, R.E., and Mc Cammon, J.A. (2009) AutoGrow: a novel algorithm for protein inhibitor design. Chem. Biol. Drug Des., 73, 168-178.
173. Damewood, J.R., Lerman, C.L., and Masek, B.B. (2010) NovoFLAP: a ligand-based de novo design approach for the generation of medicinally relevant ideas. J. Chem. Inf. Model., 50, 1296-1303.
174. Huang, Q., Li, L.L., and Yang, S.J. (2010) PhDD: a new pharmacophorebased de novo design method of drug-like molecules combined with assessment of synthetic accessibility. J. Mol. Graph. Model., 28, 775-787.
175. Pfeffer, P., Fober, T., Hüllermeier, E., and Klebe, G. (2010) GARLig: a fully automated tool for subset selection of large fragment spaces via a selfadaptive genetic algorithm. J. Chem. Inf. Model., 50, 1644-1659.
176. White, D. and Wilson, R.C. (2010) Generative models for chemical structures. J. Chem. Inf. Model., 50, 1257-1274.
177. Lippert, T., Schulz-Gasch, T., Roche, O., Guba, W., and Rarey, M. (2011) De novo design by pharmacophore-based searches in fragment spaces. J. Comput. Aided Mol. Des., 25, 931-945.
178. Wong, S.S., Luo, W., and Chan, K.C. (2011) EvoMD: an algorithm for evolutionary molecular design. IEEE/ACM Trans. Comput. Biol. Bioinform., 8, 987-1003.
179. Jiang, C., Yang, L., Wu, W.T., Guo, Q.L., and You, Q.D. (2011) De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors. Bioorg. Med. Chem., 19, 5612-5627.
180. Urich, R., Wishart, G., Kiczun, M., Richters, A., Tidten-Luksch, N., Rauh, D., Sherborne, B., Wyatt, P.G., and Brenk, R. (2013) De novo design of protein kinase inhibitors by in silico identification of hinge regionbinding fragments. ACS Chem. Biol., 8, 1044-1052.
181. Hartenfeller, M. and Schneider, G. (2011) Enabling future drug discovery by de novo design. WIREs Comput. Mol. Sci., 1, 742-759.
182. Kitchen, D.B., Decornez, H., Furr, J.R., and Bajorath, J. (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov., 3, 935-949.
183. Wang, B., Westerhoff, L.M., and Merz, K.M. Jr., (2007) A critical assessment of the performance of protein-ligand scoring functions based on NMR chemical shift perturbations. J. Med. Chem., 50, 5128-5134.
184. Coupez, B. and Lewis, R.A. (2006) Docking and scoring-theoretically easy, practically impossible? Curr. Med. Chem., 13, 2995-3003.
185. Michel, J., Foloppe, N., and Essex, J.W. (2010) Rigorous free energy calculations in structure-based drug design. Mol. Inf., 29, 570-578.
186. Schneider, G. and Böhm, H.J. (2002) Virtual screening and fast automated docking methods. Drug Discov. Today, 7, 64-70.
187. Gohlke, H. and Klebe, G. (2001) Statistical potentials and scoring functions applied to protein-ligand binding. Curr. Opin. Struct. Biol., 11, 231-235.
188. Grzybowski, B.A., Ishchenko, A.V., Shimada, J., and Shakhnovich, E.I. (2002) From knowledge-based potentials to combinatorial lead design in silico. Acc. Chem. Res., 35, 261-269.
189. Schneider, G. and Fechner, U. (2005) Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov., 4, 649-663.
190. Dean, P.M. (2007) Chemical genomics: a challenge for de novo drug design. Mol. Biotechnol., 37, 237-245.
191. Mauser, H. and Guba, W. (2008) Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discov. Dev., 11, 365-374.
192. Jorgensen, W.L. (2009) Efficient drug lead discovery and optimization. Acc. Chem. Res., 42, 724-733.
193. Pirard, B. (2011) The quest for novel chemical matter and the contribution of computer-aided de novo design. Expert Opin. Drug Discov., 6, 225-231.
194. Warr, W.A. (2011) Some trends in chem(o)informatics. Methods Mol. Biol., 672, 1-37.
195. Kutchukian, P.S. and Shakhnovich, E.I. (2010) De novo design: balancing novelty and confined chemical space. Expert Opin. Drug Discov., 5, 789-812.
196. Konteatis, Z.D. (2010) In silico fragment-based drug design. Expert Opin. Drug Discov., 5, 1047-1065.
197. Hartenfeller, M. and Schneider, G. (2011) De novo drug design. Methods Mol. Biol., 672, 299-323.
198. Sheng, C. and Zhang, W. (2013) Fragment informatics and computational fragment-based drug design: an overview and update. Med. Res. Rev., 33, 554-598.
199. Nicolaou, C.A., Kannas, C., and Loizidou, E. (2012) Multi-objective optimization methods in de novo drug design. Mini Rev. Med. Chem., 12, 979-987.
200. Beddell, C.R., Goodford, P.J., Norrington, F.E., Wilkinson, S., and Wootton, R. (1976) Compounds designed to fit a site of known structure in human haemoglobin. Br. J. Pharmacol., 57, 201-209.
201. Beddell, C.R., Goodford, P.J., Stammers, D.K., and Wootton, R. (1979) Species differences in the binding of compounds designed to fit a site of known structure in adult human haemoglobin. Br. J. Pharmacol., 65, 535-543.
202. Gund, P., Wipke, W.T., and Langridge, R. (1974) Computer searching of a molecular structure file for pharmacophoric patterns. Comput. Chem. Res. Educ. Technol., 3, 5-21.
203. Martin, Y.C., Bures, M.G., and Willett, P. (1990) in Reviews in Computational Chemistry, Vol. 1 (eds K. Lipkowitz and D. Boyd), Wiley-VCH Verlag GmbH, Weinheim, pp. 213-263.
204. Sheridan, R.P. and Venkataraghavan, R. (1987) Designing novel nicotinic agonists by searching a database of molecular shapes. J. Comput. Aided Mol. Des., 1, 243-256.
205. Lewis, R.A. and Dean, P.M. (1989) Automated site-directed drug design: the formation of molecular templates in primary structure generation. Proc. R. Soc. London, Ser. B, 236, 141-162.
206. Van Drie, J.H., Weininger, D., and Martin, Y.C. (1989) ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of threedimensional molecular structures. J. Comput. Aided Mol. Des., 3, 225-240.
207. Bartlett, P.A., Shea, G.T., Telfer, S.J., and Waterman, S. (1989) in Molecular Recognition in Chemical and Biological Problems, Vol. 78 (ed. S.M. Roberts), Royal Society of Chemistry, London, pp. 182-196.
208. Lauri, G. and Bartlett, P.A. (1994) CAVEAT: a program to facilitate the design of organic molecules. J. Comput. Aided Mol. Des., 8, 51-66.
209. Carhart, R.E., Smith, D.H., Gray, N.A.B., Nourse, J.G., and Djerassi, C. (1981) GENOA: a computer program for structure elucidation utilizing overlapping and alternative substructures. J. Org. Chem., 46, 1708-1718.
210. Wise, M., Cramer, R.D., Smith, D., and Exman, I. (1983) in Quantitative Approaches to Drug Design (ed. J.C. Dearden), Elsevier, Amsterdam, pp. 145-146.
211. Goodford, P.J. (1995) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem., 28, 849-857.
212. Miranker, A. and Karplus, M. (1991) Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins, 11, 29-34.
213. Kuntz, I.D., Blaney, J.M., Oatley, S.J., Langridge, R., and Ferrin, T.E. (1982) A geometric approach to macromoleculeligand interactions. J. Mol. Biol., 161, 269-288.
214. Jackson, R.C. (1995) Update on computer-aided drug design. Curr. Opin. Biotechnol., 6, 646-651.
215. Böhm, H.J. (1996) Current computational tools for de novo ligand design. Curr. Opin. Biotechnol., 7, 433-436.
216. Bohacek, R.S. and Mc Martin, C. (1997) Modern computational chemistry and drug discovery: structure generating programs. Curr. Opin. Chem. Biol., 1, 157-161.
217. Marrone, T.J., Briggs, J.M., and Mc Cammon, J.A. (1997) Structurebased drug design: computational advances. Annu. Rev. Pharmacol. Toxicol., 37, 71-90.
218. Kubinyi, H. (1998) Combinatorial and computational approaches in structurebased drug design. Curr. Opin. Drug Discov. Dev., 1, 16-27.
219. Moon, J.B. and Howe, W.J. (1991) Computer design of bioactive molecules: a method for receptorbased de novo ligand design. Proteins, 11, 314-328.
220. Böhm, H.J. (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput. Aided Mol. Des., 6, 61-78.
221. Böhm, H.J. (1992) LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput. Aided Mol. Des., 6, 593-606.
222. Nestor, J.J. Jr., (2009) The medicinal chemistry of peptides. Curr. Med. Chem., 16, 4399-4418.
223. Vanhee, P., van der Sloot, A.M., Verschueren, E., Serrano, L., Rousseau, F., and Schymkowitz, J. (2011) Computational design of peptide ligands. Trends Biotechnol., 29, 231-239.
224. Renukuntla, J., Vadlapudi, A.D., Patel, A., Boddu, S.H., and Mitra, A.K. (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm., 447, 75-93.
225. Kandil, S., Biondaro, S., Vlachakis, D., Cummins, A.C., Coluccia, A., Berry, C., Leyssen, P., Neyts, J., and Brancale, A. (2009) Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg. Med. Chem. Lett., 19, 2935-2937.
226. Rogers-Evans, M., Alanine, A., Bleicher, K., Kube, D., and Schneider, G. (2004) Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis. QSAR Comb. Sci., 26, 426-430.
227. Schneider, G., Neidhart, W., Giller, T., and Schmid, G. (1999) 'Scaffoldhopping' by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed., 38, 2894-2896.
228. Alig, L., Alsenz, J., Andjelkovic, M., Bendels, S., Benardeau, A., Bleicher, K., Bourson, A., David-Pierson, P., Guba, W., Hildbrand, S., Kube, D., Lübbers, T., Mayweg, A.V., Narquizian, R., Neidhart, W., Nettekoven, M., Plancher, J.M., Rocha, C., Rogers-Evans, M., Röver, S., Schneider, G., Taylor, S., and Waldmeier, P. (2008) Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. J. Med. Chem., 51, 2115-2127.
229. Mitchell, W. and Matsumoto, S. (2011) Large-scale integrated super-computing platform for next generation virtual drug discovery. Curr. Opin. Chem. Biol., 15, 553-559.
230. Park, H., Ryu, S.E., and Kim, S.J. (2012) Structure-based de novo design of Eya2 phosphatase inhibitors. J. Mol. Graph. Model., 38, 382-388.
231. Park, H., Jeong, Y., and Hong, S. (2012) Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors. Bioorg. Med. Chem. Lett., 22, 1027-1030.
232. Ishchenko, A., Liu, Z., Lindblom, P., Wu, G., Jim, K.C., Gregg, R.D., Claremon, D.A., and Singh, S.B. (2012) Structure-based design technology contour and its application to the design of renin inhibitors. J. Chem. Inf. Model., 52, 2089-2097.
233. van der Horst, E., Marqúes-Gallego, P., Mulder-Krieger, T., van Veldhoven, J., Kruisselbrink, J., Aleman, A., Emmerich, M.T., Brussee, J., Bender, A., and Ijzerman, A.P. (2012) Multi-objective evolutionary design of adenosine receptor ligands. J. Chem. Inf. Model., 52, 1713-1721.
234. Ekins, S. and Williams, A.J. (2011) Finding promiscuous old drugs for new uses. Pharm. Res., 28, 1785-1791.
235. Keppner, S., Proschak, E., Schneider, G., and Spänkuch, B. (2009) Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem, 4, 1806-1809.
236. Schneider, G., Geppert, T., Hartenfeller, M., Reisen, F., Klenner, A., Reutlinger, M., Hähnke, V., Hiss, J.A., Zettl, H., Keppner, S., Spänkuch, S., and Schneider, P. (2011) Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors. Future Med. Chem., 3, 415-424.
237. Spänkuch, B., Keppner, S., Lange, L., Rodrigues, T., Zettl, H., Koch, C.P., Reutlinger, M., Hartenfeller, M., Schneider, P., and Schneider, G. (2013) Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads. Angew. Chem. Int. Ed., 52, 4676-4681.
238. Rodrigues, T., Roudnicky, F., Koch, C.P., Kudoh, T., Reker, D., Detmar, M., and Schneider, G. (2013) De novo design and optimization of Aurora A kinase inhibitors. Chem. Sci., 4, 1229-1233.
239. Loving, K., Alberts, I., and Sherman, W. (2010) Computational approaches for fragment-based and de novo design. Curr. Top. Med. Chem., 10, 14-32.
240. Langdon, S.R., Ertl, P., and Brown, N. (2010) Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol. Inf., 29, 366-385.
241. Bailey, D. and Brown, D. (2001) High-throughput chemistry and structure-based design: survival of the smartest. Drug Discov. Today, 6, 57-59.
242. Bleicher, K.H., Böhm, H.J., Müller, K., and Alanine, A.I. (2003) Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov., 2, 369-378.
243. Schneider, G. (2010) Virtual screening: an endless staircase? Nat. Rev. Drug Discov., 9, 273-276.
244. Krüger, B.A., Dietrich, A., Baringhaus, K.H., and Schneider, G. (2009) Scaffold-hopping potential of fragmentbased de novo design: the chances and limits of variation. Comb. Chem. High Throughput Screening, 12, 383-396.
245. Sheridan, R.P., Rusinko, A. III, Nilakantan, R., and Venkataraghavan, R. (1989) Searching for pharmacophores in large coordinate data bases and its use in drug design. Proc. Natl. Acad. Sci. U.S.A., 86, 8165-8169.